Valbenazine: all 33 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Valbenazine in Obsessive Compulsive DisorderNot yet recruitingNCT07111988Phase 2
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
- Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical DystoniaRecruitingNCT06771323Phase 2
- Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in CanadaEnrolling by invitationNCT06312189Phase 3
- Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsRecruitingNCT05207085Phase 2
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
- Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04102579Phase 3Results posted
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedNCT03891862Phase 4Results posted
- Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette SyndromeTerminatedNCT03732534Phase 2Results posted
- The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineCompletedNCT03698331Phase 4Results posted
- Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette SyndromeTerminatedNCT03530293Phase 2Results posted
- Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedNCT03444038Phase 2Results posted
- Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedNCT03325010Phase 2Results posted
- Efficacy and Safety of MT-5199 in Subjects With Tardive DyskinesiaCompletedNCT03176771Phase 2/3Results posted
- Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeCompletedNCT02879578Phase 2Results posted
- Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaCompletedNCT02736955Phase 3Results posted
- Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette SyndromeCompletedNCT02679079Phase 2Results posted
- Safety and Efficacy Study of NBI-98854 in Adults With Tourette SyndromeCompletedNCT02581865Phase 2Results posted
- Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 3Results posted
- A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 3Results posted
- NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 2Results posted
- NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2Results posted
- NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental DisabilitiesWithdrawnNCT06107829Phase 4
- Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaTerminatedNCT05654870Phase 3
- Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompletedNCT05206513Phase 3
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedNCT05110157Phase 3
- Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With ValbenazineWithdrawnNCT05053321Phase 1
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04400331Phase 3
- Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette SyndromeCompletedNCT02256475Phase 1
- Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencyCompletedNCT01916993Phase 1
- Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy SubjectsCompletedNCT01910480Phase 1
- Efficacy and Safety of NBI-98854 in Subjects With Tardive DyskinesiaCompletedNCT01267188Phase 2